P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

Detalles Bibliográficos
Autores principales: Thavayogarajah, T., Nair, G., Balabanov, S., Manz, M. G., Müller, D., Schanz, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430518/
http://dx.doi.org/10.1097/01.HS9.0000848376.24818.fe
_version_ 1784779792050028544
author Thavayogarajah, T.
Nair, G.
Balabanov, S.
Manz, M. G.
Müller, D.
Schanz, U.
author_facet Thavayogarajah, T.
Nair, G.
Balabanov, S.
Manz, M. G.
Müller, D.
Schanz, U.
author_sort Thavayogarajah, T.
collection PubMed
description
format Online
Article
Text
id pubmed-9430518
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94305182022-08-31 P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Thavayogarajah, T. Nair, G. Balabanov, S. Manz, M. G. Müller, D. Schanz, U. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430518/ http://dx.doi.org/10.1097/01.HS9.0000848376.24818.fe Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Thavayogarajah, T.
Nair, G.
Balabanov, S.
Manz, M. G.
Müller, D.
Schanz, U.
P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
title P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
title_full P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
title_fullStr P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
title_full_unstemmed P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
title_short P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
title_sort p1379: optimization of fludarabine pharmacokincetics to reduce the relapse incidence in aml patients after allogeneic stem cell transplantation
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430518/
http://dx.doi.org/10.1097/01.HS9.0000848376.24818.fe
work_keys_str_mv AT thavayogarajaht p1379optimizationoffludarabinepharmacokinceticstoreducetherelapseincidenceinamlpatientsafterallogeneicstemcelltransplantation
AT nairg p1379optimizationoffludarabinepharmacokinceticstoreducetherelapseincidenceinamlpatientsafterallogeneicstemcelltransplantation
AT balabanovs p1379optimizationoffludarabinepharmacokinceticstoreducetherelapseincidenceinamlpatientsafterallogeneicstemcelltransplantation
AT manzmg p1379optimizationoffludarabinepharmacokinceticstoreducetherelapseincidenceinamlpatientsafterallogeneicstemcelltransplantation
AT mullerd p1379optimizationoffludarabinepharmacokinceticstoreducetherelapseincidenceinamlpatientsafterallogeneicstemcelltransplantation
AT schanzu p1379optimizationoffludarabinepharmacokinceticstoreducetherelapseincidenceinamlpatientsafterallogeneicstemcelltransplantation

Ejemplares similares